MCDA (Multi-Criteria Decision Analysis) – Polish experience and results of Poland MCDA data on late stage oncology

Aleksandra Zawodnik
MSc Pharm, PhD Candidate
Department of Experimental and Clinical Pharmacology,
Medical University of Warsaw, Warsaw, Poland

PAST – PRESENT – FUTURE of MCDA in Poland

• Ordinance by National Health Fund (2007)
• Economic Council of MoH (2012)
• Reimbursement decision criteria (2011)
• IOWISZ (Evaluation Instrument of Investment Motions in Health Care, 2016)
• The algorithm assessing the value of new anticancer drugs — the proposal of the Polish Society of Clinical Oncology and Polish Oncological Society (2015)
### Results

Polish MCDM data on oncology

- Performed June-October 2017

<table>
<thead>
<tr>
<th>Role</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Payer</td>
<td>4</td>
</tr>
<tr>
<td>Pharma</td>
<td>6</td>
</tr>
<tr>
<td>Patient</td>
<td>1</td>
</tr>
<tr>
<td>Public</td>
<td>3</td>
</tr>
<tr>
<td>Politician</td>
<td>1</td>
</tr>
<tr>
<td>Pharmacists</td>
<td>5</td>
</tr>
<tr>
<td>Physicians</td>
<td>3</td>
</tr>
</tbody>
</table>
**Poland** median weights on all criteria by all (7P) representatives

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Median *</th>
<th>Pharma6</th>
<th>Pharma4</th>
<th>Pharma5</th>
<th>Pharma3</th>
<th>Pharma2</th>
<th>Pharma1</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt. Pref.</td>
<td>0.1499</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strategic</td>
<td>0.0542</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unmet Need</td>
<td>0.2042</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety</td>
<td>0.2227</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budg. Imp.</td>
<td>0.113</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy</td>
<td>0.256</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Poland Pharma on all criteria**

The chart illustrates the median weights on all criteria by various groups, including Patient, Public, Politician, Pharmacist, Physician, Payer, Pharma, and All. Each criterion—Efficacy, Strategic, Unmet Need, Safety, Budg. Imp., and Pt. Pref.—is represented by bars showing the weight distribution across these groups.
Poland Public on all criteria

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Median</th>
<th>Public1</th>
<th>Public2</th>
<th>Public3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt. Pref.</td>
<td>0.1503</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strategic</td>
<td>0.0707</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unmet Need</td>
<td>0.225</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety</td>
<td>0.117</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budg. Imp.</td>
<td>0.1957</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy</td>
<td>0.2413</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Poland median weights on all criteria

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt. Pref.</td>
<td>0.2167</td>
</tr>
<tr>
<td>Strategic</td>
<td>0.1083</td>
</tr>
<tr>
<td>Unmet Need</td>
<td>0.1833</td>
</tr>
<tr>
<td>Safety</td>
<td>0.2217</td>
</tr>
<tr>
<td>Budg. Imp.</td>
<td>0.065</td>
</tr>
<tr>
<td>Efficacy</td>
<td>0.205</td>
</tr>
</tbody>
</table>
Combined data for oncology

Results
Combined data for oncology

Pharma on all criteria for oncology

- Pt. Pref.
- Strategic
- Unmet Need
- Safety
- Budg. Imp.
- Efficacy

- Austria
- Czech Republic
- Hungary
- Poland
- Ukraine
**Pharmacist on all criteria for oncology**

- **Pt. Pref.**
  - Ukraine: 0.2293
  - Hungary: 0.2483
  - Poland: 0.2327

- **Strategic**
  - Ukraine: 0.2167
  - Hungary: 0.2167
  - Poland: 0.24

- **Unmet Need**
  - Ukraine: 0.2293
  - Hungary: 0.2483
  - Poland: 0.2327

- **Safety**
  - Ukraine: 0.2293
  - Hungary: 0.2483
  - Poland: 0.2327

- **Budg. Imp.**
  - Ukraine: 0.2293
  - Hungary: 0.2483
  - Poland: 0.2327

- **Efficacy**
  - Ukraine: 0.2293
  - Hungary: 0.2483
  - Poland: 0.2327

**Patient on all criteria for oncology**

- **Pt. Pref.**
  - Hungary: 0.2167
  - Austria: 0.2167
  - Poland: 0.2167

- **Strategic**
  - Hungary: 0.24
  - Austria: 0.24
  - Poland: 0.24

- **Unmet Need**
  - Hungary: 0.24
  - Austria: 0.24
  - Poland: 0.24

- **Safety**
  - Hungary: 0.24
  - Austria: 0.24
  - Poland: 0.24

- **Budg. Imp.**
  - Hungary: 0.24
  - Austria: 0.24
  - Poland: 0.24

- **Efficacy**
  - Hungary: 0.24
  - Austria: 0.24
  - Poland: 0.24
Public on all criteria for oncology

Median on all criteria from all representatives from all included countries for oncology
Thank You very much for attention!

contact: aleksandra.zawodnik@gmail.com